Read More Pharma Industry News Immutep reports positive Phase IIb results for Eftilagimod Alfa in head and neck cancer treatment Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company, has announced encouraging results from Cohort B of… byPallavi MadhirajuJuly 14, 2024